Parathyroid Imaging
Localizing hyperfunctioning parathyroid tissue before minimally invasive surgery
Quick Answer
Parathyroid imaging localizes a hyperfunctioning gland (usually a single adenoma) in primary hyperparathyroidism to enable minimally invasive, focused parathyroidectomy — it does not make the diagnosis, which is biochemical (hypercalcemia with inappropriately normal/high PTH). Tc-99m-sestamibi (dual-phase and/or SPECT/CT) is the traditional workhorse; ¹⁸F-fluorocholine PET/CT has higher sensitivity and is increasingly first-line, especially for small, sestamibi-negative, or multiglandular disease. 4D-CT and ultrasound are complementary; concordant localization on two modalities strongly supports a single-gland operation.
Background & Pathophysiology
Primary hyperparathyroidism is usually a single adenoma (~85%), less often four-gland hyperplasia or double adenomas, and rarely carcinoma. Excess PTH drives hypercalcemia, hypophosphatemia, bone resorption, and stones. Secondary/tertiary hyperparathyroidism (renal disease) involves multigland hyperplasia. Imaging matters only once surgery is planned — to convert a bilateral neck exploration into a targeted operation, often guided by intraoperative PTH monitoring (>50% drop confirms cure).
Clinical & Laboratory
Diagnosis is biochemical: hypercalcemia + inappropriately normal/high PTH (with low phosphate; elevated 24-h urine calcium excludes FHH). Symptoms — "stones, bones, groans, psychiatric moans" — or asymptomatic. Vitamin D repletion and FHH (low urine calcium, familial) must be considered before surgery.
Imaging Techniques
- Dual-phase sestamibi: adenomas retain sestamibi longer than normal thyroid (more mitochondria/oxyphil cells); early and delayed images show persistent focal uptake as thyroid activity washes out.
- Sestamibi SPECT/CT: adds anatomic localization — ectopic (mediastinal, retroesophageal, intrathymic) glands.
- ¹⁸F-fluorocholine PET/CT: higher sensitivity, particularly for small, sestamibi-negative, and multiglandular disease — increasingly preferred/first-line.
- 4D-CT / ultrasound: anatomic adjuncts; US operator-dependent; 4D-CT good for ectopic/re-operative cases.
Interpretation & Decision
Concordant localization (e.g., sestamibi + US, or fluorocholine + 4D-CT) strongly supports a focused, single-gland operation. A negative scan does not exclude disease — small or multiglandular adenomas are missed — and such patients may still proceed to bilateral exploration. Coexisting thyroid nodules are the classic sestamibi false positive (thyroid also concentrates the tracer).
Differential Diagnosis (of uptake)
Parathyroid adenoma vs thyroid nodule/adenoma (false positive), lymph node, thymus, and (for choline PET) other choline-avid tissue. Biochemical mimics: FHH, malignancy-associated hypercalcemia (PTHrP), vitamin D issues.
Reporting Checklist
- State the technique (dual-phase sestamibi ± SPECT/CT; fluorocholine PET/CT) and localization (side, level, ectopic sites).
- Report concordance across modalities.
- Explicitly note that imaging localizes, not diagnoses, and a negative scan does not exclude disease.
- Flag coexisting thyroid nodules as potential false positives.
Common Pitfalls
- Coexisting thyroid nodules causing sestamibi false positives.
- Small, multiglandular (hyperplasia), or ectopic glands missed — a negative scan does not exclude disease.
- Recent iodinated contrast / thyroid disease degrading interpretation.
- Treating imaging as diagnostic rather than localizing.
Board Pearls
Parathyroid imaging localizes a hyperfunctioning gland to enable a focused, minimally invasive parathyroidectomy — it does not make the diagnosis (that is biochemical: hypercalcemia + inappropriately normal/high PTH). Tc-99m-sestamibi (dual-phase ± SPECT/CT) is the traditional workhorse; ¹⁸F-fluorocholine PET/CT is more sensitive (small/sestamibi-negative/multiglandular) and increasingly first-line.
Concordant localization on two modalities strongly supports a single-gland operation, and intraoperative PTH (>50% fall) confirms cure. But a negative scan does not exclude disease — small or multiglandular adenomas are missed.
The classic sestamibi false positive is a coexisting thyroid nodule (thyroid takes up the tracer); SPECT/CT and fluorocholine PET help. SPECT/CT is essential for ectopic glands (mediastinal, retroesophageal, intrathymic), and 4D-CT is valuable in re-operative/negative-scan cases. Adenomas retain sestamibi because of their mitochondria-rich oxyphil cells.
Related Pages
- Tracer: Tc-99m-sestamibi; related: MEN syndromes, thyroid imaging.
Figure / Diagram Suggestions
- A dual-phase washout schematic (adenoma retention vs thyroid washout).
- An ectopic parathyroid location map (mediastinal, retroesophageal, intrathymic).
- A concordance matrix (sestamibi/US/fluorocholine/4D-CT).
Self-Check
Q1. Does a positive parathyroid scan make the diagnosis of primary hyperparathyroidism?
Answer: No — the diagnosis is biochemical (hypercalcemia + inappropriately normal/high PTH); imaging only localizes for surgery.
Q2. Why do parathyroid adenomas retain sestamibi longer than normal thyroid on dual-phase imaging?
Answer: Their mitochondria-rich oxyphil cells retain the tracer while thyroid activity washes out on delayed images.
Q3. When is fluorocholine PET/CT particularly advantageous over sestamibi?
Answer: For small, sestamibi-negative, or multiglandular disease — it has higher sensitivity and is increasingly first-line.
Q4. A parathyroid scan is negative but biochemistry confirms primary hyperparathyroidism. Next step?
Answer: A negative scan does not exclude disease — proceed with additional imaging (4D-CT/fluorocholine) or bilateral neck exploration.
Evidence & sources
https://nuc.med/parathyroid/ Report an issue